Lupin trades high on the bourses

16 Mar 2016 Evaluate

Lupin is currently trading at Rs. 1734.20, up by 7.60 points or 0.44% from its previous closing of Rs. 1726.60 on the BSE.

The scrip opened at Rs. 1735.50 and has touched a high and low of Rs. 1741.60 and Rs. 1698.75 respectively. So far 141260 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1589.40 on 14-May-2015.

Last one week high and low of the scrip stood at Rs. 1874.30 and Rs. 1698.75 respectively. The current market cap of the company is Rs. 78149.38 crore.

The promoters holding in the company stood at 46.53% while Institutions and Non-Institutions held 43.56% and 9.92% respectively.

Lupin has completed its acquisition of privately held US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS). The company had announced the acquisition on July 23rd 2015. The acquisition enhances the company’s scale in the US generic market and also broadens the company’s pipeline in dermatology, controlled substance products and other high-value and niche generics. GAVIS brings to the company a highly skilled US based Manufacturing & Research organization which would complement the company’s Coral Springs, Florida based R&D center for Inhalation. GAVIS’s New Jersey based manufacturing facility also becomes the company’s first manufacturing site in the US.

New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. GAVIS has 62 ANDA filings pending approval with the US FDA and a pipeline of over 65+ products under development. 72% of these filings pending approvals represent niche dosage forms with 18 Para IVs and 8 FTFs products. GAVIS’s pending approvals address a market of over USD 9 billion.

The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with the US FDA, addressing a USD 63.8 billion market. The company has 37 First-to-File (FTF) products which includes 17 exclusive FTF opportunities. The company and Gavis combined would now have over 45 FTFs.

Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×